ERAS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Erasca Inc (ERAS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive momentum, recent bullish analyst upgrades, and a promising pipeline in the RAS inhibitor space. Despite weak financials, the long-term growth potential and recent collaboration with Tango Therapeutics provide a compelling case for investment.
The stock is in a bullish trend with MACD above 0 and positively expanding, RSI at 83.459 indicating overbought conditions, and moving averages showing a bullish alignment (SMA_5 > SMA_20 > SMA_200). The current price is above the pivot level of 14.025, with resistance levels at 15.492 and 16.398.
Collaboration with Tango Therapeutics to test ERAS-0015 for MTAP-deleted RAS-mutant cancers, which could lead to significant advancements in the company's pipeline.
Multiple analyst upgrades with increased price targets and positive outlooks on the RAS inhibitor portfolio.
Bullish technical indicators and strong price momentum.
Weak financial performance with no revenue and a net income loss of -$30.6M in Q3
Overbought RSI levels suggest the stock may be due for a short-term pullback.
The company reported no revenue growth in Q3 2025, with net income dropping by -1.88% YoY to -$30.6M. EPS remained negative at -0.11. Gross margin was 0%, reflecting the company's pre-revenue stage.
Analysts are increasingly bullish on Erasca, with multiple upgrades and raised price targets. Guggenheim raised its target to $12, Mizuho to $16, and Morgan Stanley to $10, citing promising clinical data and a strong RAS inhibitor pipeline. The consensus is positive, with expectations of significant growth potential in the long term.
